Clinical trials: Obesity and Overweight
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00116740
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Obesity
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in…
- Trial name
- NCT03586843
- Testing
- JNJ-64565111
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Obesity
Injection Site Pain Comparison of Excipient Solutions
The purpose of this study is to investigate different solutions used to inject drugs under the skin. The solutions used in the study do not contain the drugs they will be used for, but they do contain excipients, which are…
- Trial name
- NCT04482725
- Testing
- Trial product 1, Trial product 2, Trial product 3
- Where
- Netherlands
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
This study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. This study also tests how semaglutide 50 mg works on appetite, control of eating (such as cravings and…
- Trial name
- NCT05236517
- Testing
- Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Obesity
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
The purpose of this study is to assess the safety and weight loss effect of lorcaserin at the end of the first year of treatment (Week 48) in overweight and Chinese adult obese patients compared to placebo.
- Trial name
- NCT03720574
- Testing
- Lorcaserin 10 mg BID
- Where
- 9 sites in China
- Volunteers
- 100 people
- Sponsor
- Kanion & Huawe Medicine Co.,Ltd
Obesity
A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112
1. Study Objective <Part 1> To evaluate the safety and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after multiple oral administration in healthy female subjects.
- Trial name
- NCT04703764
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaceum
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Hypertension
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of…
- Trial name
- NCT06948422
- Testing
- Orforglipron
- Where
- 100 sites in United States, Argentina and 9 more
- Volunteers
- 974 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 in Overweight and Obese Participants
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
- Trial name
- NCT06345066
- Testing
- Tirzepatide, LY3841136
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
- Trial name
- NCT06500299
- Testing
- HDM1002 100 mg QD, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight, Obesity
A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants
This study is a single-dose, open-label, non-randomized, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with varying…
- Trial name
- NCT07916194
- Testing
- Zovaglutide
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Obesity, Overweight
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight.
- Trial name
- NCT07808073
- Testing
- LY4329090
- Where
- 3 sites in United States, Singapore
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Gastrointestinal Dysfunction
A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese Adults
The present study is a randomized, double-blind (Double dummy), placebo-controlled, parallel-group study to assess the gut health effects of heat-killed post biotics in overweight and obese individuals
- Trial name
- NCT05820737
- Testing
- EF2001, beLP1
- Where
- 9 sites in India
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Obesity
A Study of LY3532226 in Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity.
- Trial name
- NCT06557356
- Testing
- LY3532226
- Where
- 4 sites in United States, Singapore
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have…
- Trial name
- NCT00781937
- Testing
- liraglutide
- Where
- 37 sites in United States, Canada
- Volunteers
- 422 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
- Trial name
- NCT07429045
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.